DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial
Deleterious DDR alterations were associated with pathologic response following NAC in S1314. Functional validation of <i>ERCC2</i> and other DDR alterations is underway to help refine such alterations as biomarkers of NAC in patients with bladder cancer.
Authors
- Colin P. Dinney (ORCID: https://orcid.org/0000-0002-8969-711X)
- Ian M. Thompson (ORCID: https://orcid.org/0000-0003-0833-952X)
- Catherine M. Tangen (ORCID: https://orcid.org/0000-0001-8825-8660)
- Woonyoung Choi (ORCID: https://orcid.org/0000-0003-1088-9539)
- Seth P. Lerner (ORCID: https://orcid.org/0000-0002-6379-2581)
- Jonathan E. Rosenberg (ORCID: https://orcid.org/0000-0003-2637-4249)
- Megan Fong (ORCID: https://orcid.org/0000-0002-6463-1237)
- David J. McConkey (ORCID: https://orcid.org/0000-0003-1971-0638)
- Gopa Iyer (ORCID: https://orcid.org/0000-0002-5093-6099)
- Ashley Marie Regazzi (ORCID: https://orcid.org/0000-0002-6019-1852)
- Michal Sarfaty (ORCID: https://orcid.org/0000-0002-9603-3207)
- Thomas W. Flaig (ORCID: https://orcid.org/0000-0001-6145-9040)
- I-Ling Lee
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Johns Hopkins University (US)
- Baylor College of Medicine (US)
- Cornell University (US)
- Johns Hopkins Medicine (US)
- Rabin Medical Center (IL)
- Christus Health (US)
- Fred Hutch Cancer Center (US)
- Medical Center Hospital (US)
- University of Colorado Anschutz Medical Campus (US)
- The University of Texas Health Science Center at Houston (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1200/po.24.00287
- Citations
- 7
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 4.01
Funders
- American Society of Clinical Oncology
- Mirati Therapeutics
- Loxo Oncology
- National Cancer Institute